Hikma Expands Injectable Portfolio with Furosemide Launch
Hikma launches Furosemide Injection in unique dosages for edema and broadens its U.S. injectable portfolio.
Hikma Pharmaceuticals has announced the U.S. launch of Furosemide Injection, USP, in multiple dosage forms, including the first FDA-approved 50mL and 100mL presentations. This medication is indicated for the treatment of edema in adults and pediatric patients caused by conditions like heart failure, liver cirrhosis, and renal disease, as well as for acute pulmonary edema.
The introduction broadens Hikma's extensive injectable medicine portfolio, which includes over 160 products. U.S. sales for key Furosemide Injection presentations reached approximately $30 million in the 12 months ending September 2024, per IQVIA data.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion